US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible signal to ...
US drug maker Eli Lilly is cutting its investment in a German factory by half. This decision follows new healthcare cost-cutting laws in Germany. The company CEO called the reforms a bad signal for the industry. This move impacts Germany's industrial plans. The factory will now operate at reduced capacity with fewer jobs. Other companies are also reconsidering local investments.
US drug maker Eli Lilly is cutting its investment in a German factory by half. This decision follows new healthcare cost-cutting laws in Germany. The company CEO called the reforms a bad signal for the industry. This move impacts Germany's industrial plans. The factory will now operate at reduced capacity with fewer jobs. Other companies are also reconsidering local investments.
